The Defense Logistics Agency (DLA) awarded a firm fixed-price delivery order contract worth up to $8,576.28 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of NEXPLANON 68 MG IMPLANTS. This delivery order is part of a larger indefinite delivery contract (IDC) valued at up to $499,999,999 that DMS Pharmaceutical Group holds with the DLA under the SPE2DB program, which enables the DLA to issue delivery orders for a comprehensive range of pharmaceutical items to support the medical supply needs of military healthcare facilities worldwide. The contract has no set-aside designation and is expected to be completed by August 15, 2024. Through this and other prime vendor contracts, DMS Pharmaceutical Group provides routine and critical medications, including branded and generic prescription drugs, over-the-counter products, biologics, and medical supplies, to the Department of Defense (DoD) and Department of Veterans Affairs (VA) healthcare facilities.
Generated 10/27/24, 3:41 AM